

REMARKS

Claims 1-11 are pending in the present application.

The rejection of Claims 1-11 under 35 U.S.C. §112, first paragraph (written description), is obviated by amendment.

In the Office Action, the Examiner has objected to the language “in a protein that has an amino acid sequence of SEQ ID NO: 1.” The Examiner has unbelievably interpreted this phrase to be directed to fragments (e.g., dipeptides, tripeptides, etc.) of SEQ ID NO: 1. Although Applicants believe this interpretation to be completely without merit, they have nonetheless rewritten this phrase as “in a protein that has the amino acid sequence of SEQ ID NO: 1.”

In view of the present amendment, Applicants request withdrawal of this ground of rejection.

The objection to the specification is believed to be obviated by the amendment of the Brief Description of the Drawings to specifically indicate the residue numbers of SEQ ID NO:1 that correspond to the fragments appearing in Figures 2 and 3.

Acknowledgment that this ground of rejection has been withdrawn is requested.

Applicants submit that the present application is now in condition for allowance.

Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter
Attorney of Record
Registration No. 32,884

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)

Vincent K. Shier, Ph.D.
Registration No. 50,552